Topic: Parkinson's disease
Based on phase 2 data, a Georgetown University team showed that Tasigna reduces toxic protein clumps and restores dopamine metabolism in Parkinson's.
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.
Axial Biotherapeutics raised $25 million to fund programs aimed at the gut microbiome, to treat Parkinson’s disease and autism spectrum disorder.
Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.
Cerevel Therapeutics is bringing on Otsuka’s Raymond Sanchez, to serve as chief medical officer and take its CNS assets into phase 3.
Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its bid to become a player at the cutting edge of genetic medicine.
The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets.
Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.
Rheostat Therapeutics raised $23 million to develop treatments for neurodegenerative and rare diseases by targeting the cell’s garbage disposal.